Emerald Health Therapeutics Completing Planting in Recently Fully-Licensed, Wholly-Owned Growing Facilities
26 Novembro 2019 - 9:00AM
Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX:
EMHTF) has completed planting at its indoor Québec facility,
Verdélite, and expects to complete planting in the next days in the
first of its two greenhouses in Metro Vancouver, allowing for
transition into the commercial phase of these operations and a
significant increase in quality cannabis production with
approximately 7,500kg of product output targeted for these
facilities in 2020.
The 88,000 square foot indoor Verdélite facility
consists of 21 grow rooms with precision-controlled environments
and 16 processing rooms, which became fully licensed in October.
The growing area is equipped to produce 4,800 kg of high-quality
craft cannabis annually, and Verdélite’s established packaging and
processing lines are built to process the targeted production
volume and a wide diversity of value-added products. Verdélite’s
marketing strategy is focused on building differentiated brands
with a unique Québec identity and targeting consumers seeking
premium dried flower and other value-added cannabis products for
both adult-use and health and wellness benefits.
Emerald’s Metro Vancouver operation encompasses
156,000 square feet in two greenhouses, and 12 acres of outdoor
cultivation area that became licensed in the summer. The first of
its two 78,000 square foot greenhouses received its full
cultivation license in October and organic certification in
November. This facility will organically grow multiple strains of
unique high-THC and high-CBD cannabis to expand Emerald’s product
line and will be particularly focused on serving medical customers
and adult-use consumers seeking health and wellness benefits.
“Our strategy to have multiple complementary
operations is maturing and we are transitioning into commercial
production in all our facilities,” said Riaz Bandali, President
& Chief Executive Officer of Emerald. “As we move into full
production, and with our nationwide distribution network in place
and international market opportunities such as our recently
announced Danish sales agreement, we expect sales of our
differentiated Emerald cannabis products from these expanded
facilities to start in the first quarter of 2020 and ramp up
significantly through the year.”
About Emerald Health Therapeutics,
Inc.
Emerald Health Therapeutics, Inc. (EHT) is
committed to creating new consumer experiences with recreational
and wellness-oriented cannabis products. With an emphasis on
innovation and production excellence, Emerald has built a platform
of distinct operating assets designed to uniquely serve the
Canadian marketplace and international opportunities.
EHT’s 50%-owned Pure Sunfarms (PSF) in Delta,
BC, focused on high quality, affordably priced products, is in full
production in its first 1.1M s.f. greenhouse, with a second 1.1M
s.f. greenhouse planned to be in full production by the end of
2020. Emerald’s Verdélite premium craft operation is fully licensed
and in full production in its 88,000 s.f. indoor facility in
Québec. Its Metro Vancouver health & wellness-oriented organic
greenhouse and outdoor operation is expanding to full production in
the first of two 78,000 s.f. buildings. Its Emerald Health Naturals
joint venture is creating a completely new wellness product
category with its non-cannabis endocannabinoid-supporting product
line and is expanding distribution across Canada. The executive
team is highly experienced in life sciences, product development,
large-scale agri-business, and marketing.
Please visit www.emeraldhealth.ca for more information or
contact: Jenn Hepburn, Chief Financial Officer (800) 757 3536 Ext.
#5
Emerald Investor Relations (800) 757 3536 Ext.
#5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include expansion and launch of Pure Sunfarms product lines; Pure
Sunfarms securing distribution in additional provinces; Pure
Sunfarms production of oils; obtaining required regulatory
approvals; production and processing capacity of various
facilities; expansion or conversion of facilities and the timing
thereof; obtaining additional cultivation licenses and other
permits; receipt of hemp deliveries; payments of amounts owed to
and owed by Emerald; resolution of disputes; broadening
distribution of non-cannabis endocannabinoid products; and
anticipated production costs.
We cannot guarantee that any forward-looking
statement will materialize, and readers are cautioned not to place
undue reliance on these forward-looking statements. These
forward-looking statements involve risks and uncertainties related
to, among other things, results of operations; changes in business
focus and strategy; agreements with third parties; changes of law
and regulations; changes of government; failure to obtain
regulatory approvals or permits; failure to obtain necessary
financing; results of production and sale activities; changes in
prices and costs of inputs; demand for labour; demand for products;
failure of counter-parties to perform contractual obligations; as
well as the risk factors described in the Company’s annual
information form and other regulatory filings. The forward-looking
statements contained in this press release represent our
expectations as of the date hereof. Forward-looking statements are
presented for the purpose of providing information about
management's current expectations and plans and allowing investors
and others to obtain a better understanding of our anticipated
operating environment. Readers are cautioned that such information
may not be appropriate for other purposes. The Company undertakes
no obligations to update or revise such statements to reflect new
circumstances or unanticipated events as they occur, unless
required by applicable law.
Emerald Health Therapeut... (TSXV:EMH)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Emerald Health Therapeut... (TSXV:EMH)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024